Aims: As there are only a few existing experimental studies on symptom-triggered therapy for patients with alcohol withdrawal, we investigated the effectiveness of symptom-triggered detoxification regarding the use and dosage of benzodiazepine and withdrawal complications in a naturalistic clinical setting of a specialized treatment center for alcohol use disorder. Methods: In total, 301 charts of patients who entered residential treatment for alcohol withdrawal were included in the retrospective analysis. Charts of 176 patients treated with the Alcohol Withdrawal-Scale (AWS) were compared to the charts of 125 patients treated with treatment as usual (TAU) before the implementation of AWS. Sociodemographical and clinical variables, previous detoxifications and complications, duration of treatment, use and dose of benzodiazepine and other withdrawal medication, complications and premature discontinuation of treatment were abstracted from the patients' medical records. Results: The two groups did not differ in any demographical or clinical variables measured upon treatment admission. The total percentage of patients being treated with benzodiazepines during detoxification decreased from 78.4 to 38.6% after the implementation of the AWS. The implementation of the AWS significantly reduced the duration of the acute detoxification from 136 to 66 h, and the use, duration and dose of benzodiazepine by nearly two-thirds while complications and treatment discontinuation remained unvaryingly. Healthcare costs for detoxification were reduced by half per patient. Conclusions: The findings indicate that symptom-triggered treatment for alcohol withdrawal is safe and effective in a naturalistic clinical setting and significantly reduces healthcare costs and the risk for overmedicating patients.
INTRODUCTION
Alcohol use disorder (AUD) is a chronic disease that is the third largest factor of the burden of disease in western countries (McLellan et al., 2000) . Not only does it cause suffering and pain to the patients and to their relatives but AUD also leads to tremendous social costs. In Switzerland,~17,200 persons are detoxified every year for AUD in a stationary setting (Wicki and Stucky, 2014) . The first step in AUD treatment is detoxification to pursue the following three goals: (i) initiating abstinence, (ii) reducing withdrawal symptoms and severe complications and (iii) retraining the patient in treatment (Kosten and O'Connor, 2003) . Patients with severe AUD who are hospitalized for detoxification are at high risk to suffer from an alcohol withdrawal syndrome (Falkai and Wittchen, 2015) . However, <10% of the patients experience serious complications such as epileptic seizures or delirium tremens during withdrawal (Falkai and Wittchen, 2015) .
There is extensive evidence that benzodiazepines are the drug of choice to effectively reduce acute symptoms of alcohol withdrawal and prevent complications due to their sedating and anticonvulsant effects (Mayo-Smith, 1997; Holbrook et al., 1999; Kosten and O'Connor, 2003) . However, the list of possible side effects of the use of benzodiazepines is substantial, in particular its highly addictive potential. Thus, caution will have to be used if patients with a current or lifetime history of substance abuse are treated by benzodiazepines (Longo and Johnson, 2000) . The risk of developing a benzodiazepine dependency depends on the dosage, potency and duration of the benzodiazepine treatment (Longo and Johnson, 2000; Kosten and O'Connor, 2003) . A nationwide survey of inpatient treatment practices for alcohol withdrawal showed that most patients treated in hospitals receive a long-acting benzodiazepine on a predetermined fixed dosage schedule with additional medication available on an as-needed basis (Saitz et al., 1995) even though many patient undergo alcohol withdrawal safely and comfortably without pharmacological intervention (Saitz et al., 1994) . Withdrawal symptoms can be quantified to allow symptomtriggered therapy, which consists of monitoring symptoms of withdrawal and provide medication with a benzodiazepine only when alcohol withdrawal symptoms exceed a certain threshold of severity (Saitz et al., 1994; Reoux and Miller, 2000; Kosten and O'Connor, 2003) . The prescription of symptom-triggered medication administration effectively treats uncomplicated alcohol withdrawal and reduces the risk of over-or undermedication of patients (Saitz et al., 1994; Reoux and Miller, 2000; Reoux and Oreskovich, 2006) . However, this approach requires careful and frequent monitoring using a validated withdrawal-symptom scale.
The probably most administered assessment scale to measure the severity of alcohol withdrawal symptoms is the revised Clinical Institute Withdrawal Assessment Scale for Alcohol (CIWA-Ar Sullivan et al., (1989) ), which has been proven to be a reliable, valid and economic scale in a broad of clinical and research settings (Wartenberg et al., 1990; Saitz et al., 1994; Reoux and Miller, 2000; Reoux and Oreskovich, 2006) . There are several assessment scales that are revised versions of the CIWA or newly developed assessment scales on the basis of the CIWA such the AlcoholWithdrawal-Scale by Wetterling and Veltrup (1997) . There is evidence from several studies that symptom-triggered treatment reduces both withdrawal medication and duration of treatment compared to fixed-schedule treatment and helps avoiding over-or undertreatment of patients (Sullivan et al., 1989; Wartenberg et al., 1990; Saitz et al., 1994; Reoux and Miller, 2000; Reoux and Oreskovich, 2006; Daeppen et al., 2002; Bonnet et al., 2011) .
Although, the AWS was introduced more than 10 years ago, symptom-triggered detoxification has been rarely investigated and has been far too little put into practice. The purpose of this study was to evaluate the effectiveness of the symptom-triggered therapy conducted with the Alcohol-Withdrawal-Scale (AWS) developed by Wetterling and Veltrup (1997) in a naturalistic clinical setting of a specialized treatment center for AUD. We analyzed the patients' charts before and after the implementation of the AWS in a specialized treatment center for AUD with regard to the duration, the use of benzodiazepines and other medications as well as complications during the detoxification and the costs of treatment. The AWS is a slightly modified version of the CIWA-Ar, translated into German including two additional subscales assessing somatic and mental symptoms of withdrawal (Wetterling and Veltrup, 1997) . Considering prior research, it was assumed that the implementation of the AWS leads to shorter duration of the acute detoxification and reduced use and dosage of benzodiazepines, which in turn results in reduced healthcare costs. Frequencies of complications, anti-craving medication and premature discontinuation of therapy were expected to be the same in both groups.
MATERIAL AND METHODS

Patients
The data of 471 former patients (305 men, 66.5%; age range 18-78 years; mean ± SD age: 46.70 ± 11.89 years), who were treated for alcohol withdrawal in a residential treatment program for AUD in Switzerland (Klinik Südhang), was retrospectively analyzed. Out of the initial 471 patients that entered the clinic in the two time periods before and after the implantation of the AWS, 170 were excluded from the analysis for the following reasons: (a) patients were already withdrawn or stopped drinking more than 24 h before treatment admission (n = 159), (b) patients of the AWS group not treated with AWS (n = 2), (c) additional chronic benzodiazepine treatment (n = 43) and (d) premature discontinuation of the therapy (n = 10). The final sample consisted of 301 eligible patients with AUD who were admitted to the clinic for detoxification treatment (203 men, age range 19-78 years; mean ± SD age: 47.06 ± 11.14). Patients were divided into two groups corresponding of two periods:
TAU-group
Consists of 125 patients (76 men, 60.8%; age range 19-78 years; mean ± SD age: 47.20 ± 11.48) who were admitted to the clinic for detoxification between the 1 of January 2012 and the 31 of December 2012 in a time period prior to the implementation of the AWS. This group received treatment as usual (TAU), which was a rather fixed scheme of benzodiazepine administration when withdrawal symptoms were present normally starting with 1-1-1 mg of lorazepam per day for the first two days followed by a reduction of 1 mg every second day. Based on the clinical evaluation the scheme was adapted by the physician in charge. Patients with weak withdrawal symptoms were observed regularly and medicated as needed.
AWS-group
This group consisted of 176 patients (127 men, 72.2%; age range 19-73 years; mean ± SD age: 46.96 ± 10.93) who entered the specialized psychiatric hospital for detoxification between the 1 of June 2014 and the 1 of June 2015. Detoxification process and administration of benzodiazepines depended on the AWS-scores as stated below.
Alcohol Withdrawal Scale
The AWS (Wetterling and Veltrup, 1997 ) is a revised version of the Clinical Institute Withdrawal Assessment for Alcohol-revised (CIWA-AR, (Sullivan et al., 1989) ). This symptom-triggered treatment for alcohol withdrawal consists of monitoring withdrawal symptoms. If alcohol withdrawal symptoms are present at a clinical level, prescription of benzodiazepine will be provided (Reoux and Miller, 2000) . The AWS is a validated objective scale consisting of 11 items assessing somatic features (pulse frequency, diastolic blood pressure, body temperature, respiratory frequency, amount of sweating and tremor) and mental symptoms (psychomotor agitation, contact, orientation, hallucinations and fear) (Wetterling and Veltrup, 1997) . The rating of each item is administered by trained nursing staff. Consistent with other symptom-triggered approaches, medication was given when the AWS-score reached six points or more and patients were reassessed every 2 h after being medicated.
According to the protocol, the assessment of AWS started when patients reached a breath alcohol concentration (BAC) ≤ 0.1‰. BAC above 1 per mil was regularly monitored. The patients received 1 mg of lorazepam each time the AWS score was higher than six points. The nursing staff ceased the assessment by the AWS after three consecutive observations whose scores were below six points every 2 h. An additional AWS was performed 24 h after the first score lower than six points, to make sure not to miss late withdrawal symptoms.
Additional withdrawal medication such as diazepam, quetiapine or chlorprothixene was administered if needed.
Procedure and Measurements
At treatment admission all patients go through a standardized treatment procedure consisting of structured interview on sociodemographic and substance related characteristics, clinical questionnaires which is followed by a diagnostic interview and somatic examination by a clinician. The structured interview comprise sociodemographic, clinical and alcohol related variables, which is a swiss-wide standardized interview for patients in a specialized hospital for SUD in Switzerland. All patients give written informed consent. All variables were retrospectively extracted from the patient's standardized charts and anonymized and all patients gave written informed consent for the use of their anonymized personal data. Thus, no clinical trial registration number nor approval by the local ethics committee was required.
Variables assessed at admission The demographic variables assessed are age, gender, marital status, work and living situation of the patient. Variables regarding patient's addiction history were dual diagnosis in addition to the AUD, the duration of alcohol dependence, the number of past in-or out-patient detoxification episodes and consumption of other substances than alcohol in the last 6 months. The information on quantity of drinking was categorized into the number of alcoholic drinks per days during the last seven and during the last 30 days, the number of drinks per week during the last 30 days and the number of drinking days during the last 90 days. The number of alcoholic drinks was calculated using standard drinks which in Switzerland comprises 10-12 g of alcohol. Harm caused by alcohol consumption were categorized into four variables: Alcoholic liver damage, psychological, neurological and physical harm. Previous complications during detoxification were classified into epileptic seizure, hallucinations or delirium tremens/predelirium. The following medical measurements were assessed at treatment admission: BAC, pulse, body mass index (BMI), liver function tests (GOT, GPT, Gamma GT) and a urine sample at admission for drug screening.
Variables assessed during detoxification process Patients filled out the Brief Symptom Checklist (BSCL, (Franke, 1995) ) within the first 3 days of their stay to assess general psychiatric symptoms. Regarding the administration of benzodiazepine, it was noted whether the patient received benzodiazepine at all or not during treatment. The administration of the two benzodiazepines lorazepam and diazepam were assessed separately in milligrams. In case of incompatibility with lorazepam, diazepam was administered. The duration of acute detoxification for those patients treated with benzodiazepines was defined as the number of hours between the time of treatment initiation and the time of treatment termination (last administration of benzodiazepine). The time on the detoxification unit was divided in two stages: (a) acute detoxification and (b) psychosocial treatment. Patients are transferred to the psychosocial treatment when no more withdrawal symptoms and no withdrawal medication are recorded by the staff. Costs were calculated on the basis of the average rates for one day in an acute psychiatric institution in Switzerland which is~655.1 ± 106.5 Swiss Francs. Complications during detoxification were assessed and categorized in epileptic seizure, hallucinations and delirium tremens or predelirum. Additional withdrawal medication such as chlorprothixene and quetiapine was recorded for each patient in chlorpromazine equivalents (CPZ) which were calculated according to Woods (Woods, 2003) . Furthermore, premature discontinuation of detoxification was recorded.
STATISTICS
The data were analyzed using SPSS version 23.0 statistical software package. T-tests for independent variables were used to compare continuous variables (means ± SD are reported). Analysis concerning the use of benzodiazepines only included patients that have been treated with the medication. Pearson's chi-square test was used to compare dichotomous variables. Kaplan-Meier curves demonstrate the time to last medication administration, and these times were compared using the log rank test. In addition, we report controlled effect size for the main outcome measurements (Cohen's d). To test possible influence of gender, a covariance analysis (ANCOVA) was carried out for the main outcome variables such as dose and duration of benzodiazepine medication and duration of detoxification process. All tests were twotailed and a probability of <0.05 was considered significant.
RESULTS
Patients
The two patient groups (TAU, AWS) did not differ regarding any demographic variables at treatment admission except of gender there was a higher percentage of men in the AWS-group compared to TAU-group (Table 1) . However, analysis of covariance showed no significant effect of gender on the interaction between the implementation of the AWS and the duration of detoxification neither the use of benzodiazepine (P > 0.243).
Furthermore, patients of both groups did not differ regarding any clinical or alcohol associated variables such as dual diagnosis, duration of dependence, consumption of other substances, quantity of drinking, measured in the number of drinks per day in the last 7 and 30 days, the number of drinks per week in the last 30 days and the number of drinking days in the last 90 days, physical and neurological damages caused by the consumption of alcohol (Table 1) . The groups were comparable considering the number of past inpatient and outpatient detoxifications, epileptic seizures or hallucinations during previous detoxifications. However, significantly more patients of the AWS-group had suffered from delirium tremens during previous detoxifications (Table 2) . No group differences were observed regarding medical and psychological measurements at treatment admission: BAC, blood pressure, BMI and liver function tests, BSCL (Tables 1, 2) .
Detoxification: duration, medication, complications and costs
The total percentage of patients being treated with benzodiazepines during acute detoxification decreased from 78.4% in the TAU-group to 38.6% in the AWS-group (χ 2 = 46.72; df = 1; P < 0.001). Analysis concerning duration and dosage of benzodiazepine only include patients actually receiving pharmacological treatment. The administration of lorazepam during withdrawal significantly decreased from 14.8 mg in the TAU-group to 5.1 mg in the AWS-group and the time between the treatment admission and last benzodiazepine administration significantly decreased from 124.2 to 45.6 h (Fig. 1, Table 3 ). Additionally, the implementation of the AWS reduced the dosage of additional withdrawal medication (CPZI) from 218.7 to 83.8 even though the percentage of patients treated with CPZI remained comparable (TAU-group: 21.6%; AWS-group: 26.1%). However, there was no difference regarding the administration of diazepam between the two groups (Table 3) . Concerning complications during detoxification (epileptic seizures, hallucinations or delirium tremens/predelirium) no differences between the TAU-group (4%) and the AWS-group (2.8%) (χ 2 = 0.31; df = 1; P < 0.580) was observed neither regarding premature discontinuation of treatment (χ 2 = 1.41; df = 1; P < 0.235).
Analysis of the duration of detoxification of all patients showed that the implementation of the AWS significantly reduced the duration of the acute detoxification from 135.9 to 65.9 h (see Table 3 ) as well as the psychosocial treatment significantly decreased from 322.4 to 266.1 h (t = 3.86; df = 299; P < 0.001). Summed up, the whole stay on the detoxification unit decreased from 19.1 to 13.8 days (see Table 3 ). Calculations of the costs for detoxification were based on an average of 655.1 ± 106.5 Swiss Francs (CHF) for 1 day in a psychiatric hospital in Switzerland. Thus, the implementation of the AWS reduced healthcare cost for the acute detoxification from 3,710.5 (±1,621.7) CHF to 1,797.8 (±1,137.4) CHF (t = 11.35; df = 207.8; P < 0.001) and for the entire stay on the detoxification unit from 12,509.8 (±4,048.1) CHF to 9,059.7 (±3,660.8) CHF per patient (t = 7.71; df = 299; P < 0.001).
DISCUSSION
The present study investigated the effectiveness, safety and costs of the symptom-triggered treatment for alcohol withdrawal using the AWS in a naturalistic clinical setting of a specialized treatment center for AUD. The systematic monitoring and rating of withdrawal symptoms revealed that less than half of the patients needed pharmacological intervention compared to patients treated with TAU. The implementation of the AWS resulted in a significant reduction of the prescription of the benzodiazepine lorazepam and additional withdrawal medication (quetiapine and chlorprothixene). The use of diazepam, and the frequency of complications and premature discontinuation of treatment were rare and remained stable for both AWS and TAU. The duration of detoxification was reduced by 50% as well as the duration of benzodiazepine use and the dose of benzodiazepine administration, which were both reduced by more than 65% in the AWS group.
These results are consistent with previous studies investigating similar scales, mostly the CIWA-AR for symptom-triggered therapy for alcohol withdrawal syndrome (Wartenberg et al., 1990; Saitz et al., 1994; Reoux and Miller, 2000; Jaeger et al., 2001; Daeppen et al., 2002) . However, compared with these studies examining the effectiveness of the CIWA-AR or CIWA-AD, the use of the AWS seems to achieve even better outcomes in terms of use of benzodiazepine administration. In a randomized double-blind controlled study in male veterans, Saitz and colleagues showed that 70% of the patients treated with symptom-triggered treatment using CIWA-AR scores were treated with benzodiazepine compared to 100% of the fixed schedule group (Saitz et al., 1994) . Comparable prevalence of benzodiazepine treatment was observed in a study by Jaeger and colleagues, in which the implementation of the CIWA-AR achieved a reduction of benzodiazepine use from 88 to 82% of the patients (Jaeger et al., 2001) . Reoux et al. compared routine hospital alcohol detoxification practice to symptom-triggered management with the CIWA-AR and showed that 11 of the 26 patients monitored with CIWA-AR and 11 out of the 14 patients treated with routine hospital practice were treated with benzodiazepines for alcohol withdrawal syndrome (Reoux and Miller, 2000) . In a further study, they compared two versions of the Clinical Institute Withdrawal Assessment for Alcohol (CIWA-AD and CIWA-Ar) and reported that~55% of the patients were treated with benzodiazepines (Reoux and Oreskovich, 2006) . Comparable to our results Daeppen et al. reported that 39% of the patients in the symptom-triggered CIWA-Ar group and 100% of the fixed-schedule group were treated with benzodiazepines (Daeppen et al., 2002) .
Regarding the effectiveness of the symptom-triggered treatment most studies confirm a significant reduction in the duration and intensity of benzodiazepine treatment as well as shorter duration of detoxification compared to fixed-schedule treatment. Only in the retrospective analysis of Jaeger on a cohort treated with TAU compared to a cohort treated with symptom-triggered therapy using *res., residential; BAC, Breath alcohol concentration ‰; GOT, aspartate aminotransferase; gamma-GT, gamma-glutamyl-transpeptidase; GPT, alanine aminotransferase. Kaplan Meier curve shows that less patients receive medication in the AWSgroup (%) and treatment time was significantly shorter in patients receiving symptom-triggered therapy (log rank test P < 0.001).
CIWA-AR no significant differences regarding duration of treatment, benzodiazepine use, total dose of benzodiazepine or total complication rate was observed (Jaeger et al., 2001) . However, symptom-triggered treatment was associated with a decreased occurrence of delirium tremens in patients with no history of delirium tremens.
Compared with previous findings (Wartenberg et al., 1990; Saitz et al., 1994; Daeppen et al., 2002; Reoux and Oreskovich, 2006) , this study is the first retrospective study conducted in a naturalistic setting of a specialized treatment center for AUD without excluding patients who did not receive any benzodiazepines during withdrawal. Analysis show that symptom-triggered treatment was not only effective for patients treated with benzodiazepines but also reduced duration of detoxification for patients without pharmacological treatment compared to TAU. Furthermore, it is the first study, which estimates the costs saved by the implementation of the AWS. Costs for the acute detoxification as well as the entire hospitalization on the detoxification unit in the specialized treatment center for AUD were reduced by~1,900 resp. 3,500 Swiss Francs per patient without the additionally reduced medication administration taken into account. Thus, for the investigated cohort of 176 patients treated with AWS, we were able to reduce health care costs bỹ 340,000 Swiss Francs for the acute detoxification and 610,000 Swiss Francs for the entire qualified detoxification treatment in 1 year. Given the fact that 17,200 patients are annually treated for AUD in Switzerland, the systematic implementation of symptomtriggered therapy for alcohol withdrawal syndrome could potentially reduce healthcare cost and would mean financial savings of millions Swiss Francs every year.
There are several potential limitations in this study that need to be addressed. This is a retrospective analysis of standardized patients' charts comparing two different serial implemented detoxification procedures and not a randomized controlled trial. Although, we attempted to account for variables that would affect outcomes, other possible confounders such as changes within the nursing staff might have an impact on the outcome. Furthermore, the study was conducted in a specialized treatment center for AUD, in which nurses were specifically trained to use the alcohol withdrawal scale. Thus, the use of the AWS in other treatment settings in which withdrawal is not encountered as frequently may not be as easy to administer. Additionally, patients with comorbid benzodiazepine or opioid withdrawal were excluded from the analysis, which limits the generalizability of the results. The calculation of the costs are based on daily bases for inpatient treatment in an acute psychiatric institution in Switzerland and do not exactly reflect the actual costs of human resources or services. Even though the implementation of the AWS results in additional nursing care and costs during the acute detoxification resulting in even more patient admissions per year, number of staff and resources remained the same after the implementation of the AWS.
Actually, more patients of the AWS-group (8.1%) reported past delirium tremens compared to TAU-group (2.4%) but a comparable amount of patients of the AWS-group (26.1%) was actually treated with antipsychotic medication compared to TAU-group (21.6%). However, the AWS-group was treated with either a lower dosage or a shorter time of drug administration most likely due to the close monitoring of the AWS during acute detoxification. Benzodiazepines still remain the treatment of choice to effectively reduce acute symptoms of alcohol withdrawal and prevent complications (MayoSmith, 1997; Holbrook et al., 1999; Kosten and O'Connor, 2003) but its highly addictive potential must be considered, especially when patients with a current or lifetime history of substance abuse are treated with benzodiazepines (Longo and Johnson, 2000) . The risk of developing a benzodiazepine dependency depends on the dosage, potency and especially duration of the benzodiazepine treatment (Longo and Johnson, 2000; Kosten and O'Connor, 2003) , thus a reduction of the use as well as dosage and duration of benzodiazepine during withdrawal is of high clinical relevance.
Detoxification in a specialized treatment center for AUD includes the acute detoxification but also a consecutive psychosocial treatment which is crucial to pursue the three goals of efficient AUD treatment: (a) initiating abstinence, (b) reducing withdrawal symptoms and severe complications (c) retraining the patient in treatment (Kosten and O'Connor, 2003) . Consequently, ongoing treatment is essentially needed thereafter to maintain abstinence. About 85-95% of patients relapse after detoxification without consecutive treatment. Thus, detoxification in specialized treatment centers for AUD have substantial advantages and is preferable to general hospitals as they shift immediately the focus to treatment when acute withdrawal is completed. During the psychosocial treatment following the acute detoxification, patients are able to gain experience in psychotherapy and get motivated to continue effective treatment including contingency management, motivational enhancement and cognitivebehavioral therapies (Longo and Johnson, 2000) . These findings suggest, that symptom-triggered treatment for alcohol withdrawal syndrome individualizes treatment, is safe, decreases treatment duration and the use of benzodiazepines and as a consequence reduces health care costs. Future research should investigate whether symptom-triggered therapy became standard in all specialized detoxification centers as well as general hospitals. Additionally, even though the use of the AWS-scale helps to reach very important changes, its use did not decrease complications as the AWS cannot be used to predict the course of detoxification. Thus, future research should address the issue of predictors as well whether the scale could be used for detoxification of other substances.
